The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project
Open accessAbstract
Background —Stroke is a leading cause of death and disability. Although clinical trials of the early lipid-lowering therapies did not demonstrate a reduction in the rates of stroke, data from recently completed statin trials strongly suggest benefit. Methods and Results —The effect of pravastatin 40 mg/d on stroke events was investigated in a prospectively defined pooled analysis of 3 large, placebo-controlled, randomized trials that included 19 768 patients with 102 559 person-years of follow-up. In all, 598 participants had a stroke during ≈5 years of follow-up. The 2 secondary prevention trials (CARE [Cholesterol And Recurrent Events] and LIPID [Long-term Intervention with Pravastatin in Ischemic Disease]) individually demonstrated reductions in nonfatal and total stroke rates. When the 13 173 patients from CARE and LIPID were combined, there was a 22% reduction in total strokes (95% CI 7% to 35%, P =0.01) and a 25% reduction in nonfatal stroke (95% CI 10% to 38%). The beneficial effect of pravastatin on total stroke was observed across a wide range of patient characteristics. WOSCOPS (West of Scotland Coronary Prevention Study, a primary prevention trial in hypercholesterolemic men) exhibited a similar, although smaller, trend for a reduction in total stroke. Among the CARE/LIPID participants, pravastatin was associated with a 23% reduction in nonhemorrhagic strokes (95% CI 6% to 37%), but there was no statistical treatment group difference in hemorrhagic or unknown type. Conclusions —Pravastatin reduced the risk of stroke over a wide range of lipid values among patients with documented coronary disease. This effect was due to a reduction in nonfatal nonhemorrhagic strokes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
(1995) · The Lancet · doi:10.1016/s0140-6736(95)92836-7 · Cited by 856
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 609
Self-citationSalonen, R., Nyyssönen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J.-S., & Salonen, J. T. (1995) · Circulation · doi:10.1161/01.cir.92.7.1758 · Cited by 540
Plehn, J. F., Davis, B. R., Sacks, F. M., Rouleau, J. L., Pfeffer, M. A., Bernstein, V., Cuddy, T. E., Moyé, L. A., Piller, L. B., Rutherford, J., et al. (1999) · Circulation · doi:10.1161/01.cir.99.2.216 · Cited by 429
Self-citationSacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
Self-citationBlauw, G. J., Lagaay, A. M., Smelt, A. H. M., & Westendorp, R. G. J. (1997) · Stroke · doi:10.1161/01.str.28.5.946 · Cited by 311
Byington, R. P., Jukema, J. W., Salonen, J. T., Pitt, B., Bruschke, A. V., Hoen, H., Furberg, C. D., & Mancini, G. B. J. (1995) · Circulation · doi:10.1161/01.cir.92.9.2419 · Cited by 283
Self-citationMacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
Self-citationReductase Inhibitor Monotherapy and Stroke Prevention
Crouse, J. R. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.12.1305 · Cited by 221
Atkins, D., Psaty, B. M., Koepsell, T. D., Longstreth, W. T., & Larson, E. B. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-2-199307150-00008 · Cited by 212
Health, United States, 1999; with health and aging chartbook
Kramarow, E. A., Lentzner, H. R., Saydah, S., Weeks, J. D., & Rooks, R. N. (1999) · University of Michigan Library Repository · Cited by 181
Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S)
Kjekshus, J., & Pedersen, T. R. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80473-1 · Cited by 173
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data
Crouse, J. R., Byington, R. P., & Furberg, C. D. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00014-8 · Cited by 122
Self-citationAn Overview of Trials of Cholesterol Lowering and Risk of Stroke
Hebert, P. R., Gaziano, J. M., & Hennekens, C. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430010054007 · Cited by 117
The PPP Project Investigators (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80259-8 · Cited by 44
Lipids and stroke: neglect of a useful preventive measure?
Papadakis, J. A., Mikhailidis, D. P., & Winder, A. F. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00222-3 · Cited by 31
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Self-citation
Metadata
- Authors
- Byington, R. P., Davis, B. R., Plehn, J. F., White, H. D., Baker, J., Cobbe, S. M., & Shepherd, J.
- Venue
- Circulation
- Published
- 2001-01-23
- Volume
- 103
- Issue
- 3
- Pages
- 387-392
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2036773140
- Cited by
- 276
- References
- 26
- FWCI
- 36.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.